Australia markets open in 1 hour 8 minutes

  • ALL ORDS

    7,107.10
    +56.10 (+0.80%)
     

  • AUD/USD

    0.7771
    +0.0022 (+0.28%)
     

  • ASX 200

    6,823.70
    +53.30 (+0.79%)
     

  • OIL

    53.06
    -0.25 (-0.47%)
     

  • GOLD

    1,868.90
    +2.40 (+0.13%)
     

  • BTC-AUD

    40,706.96
    -4,365.82 (-9.69%)
     

  • CMC Crypto 200

    626.50
    -53.41 (-7.86%)
     
Sign up NOW ✉️:

Want to master your money in 2021?

Join Yahoo Finance's 6-week bootcamp challenge!

2020 Report: Recent Advances Across COVID-19 Management, Microbiomics, Genomics, Transcriptomics, and Proteomics Technologies - ResearchAndMarkets.com

·3-min read

The "Recent Advances Across COVID-19 Management, Microbiomics, Genomics, Transcriptomics, and Proteomics Technologies" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent advances in phage therapeutics, skin microbiome, COVID-19 diagnostics and vaccines, and 3D bioprinting. It also evaluates developments across genomic, transcriptomic, and cell-based technological advances for precision medicine applications.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery, and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

  • Bacterial Infection Treatment Through Phage-based Therapeutics

  • Bacteriophage and Endolysins for Treatment of AMR

  • Skin Microbes: A Key to Enhance Skin Health and Appearance

  • Microbial Innovations for Skin Health

  • Point-of-Care COVID-19 Diagnostic Test

  • Transforming Rapid Diagnosis for Human Diseases and Agriculture

  • Machine Learning-based Algorithm for Sepsis Diagnosis

  • Digital Predictive Biomarker for Sepsis

  • Competitive DNA Hybridization and Electrochemical Technology for COVID-19 Diagnosis

  • eSensor Technology for Molecular Diagnosis

  • Finnish CE-IVD Diagnostic Test for COVID-19 and Beyond

  • Reliable Diagnosis for Small Laboratories

  • Sepsis Diagnosis Through Cell Mechanical Properties

  • Mechanophenotyping: Next Generation of Diagnosis

  • German mRNA-based Vaccine for COVID-19

  • mRNA Vaccines: A Potential Therapeutics for a Range of Diseases

  • Lipid-enabled mRNA Delivery System

  • Lipid-enabled mRNA Delivery System for COVID-19

  • Cost-effective COVID-19 Testing Kits

  • Academic Collaborations to Develop Diagnostic Kits

  • Technology Attributes

  • Nicotine-related Brain Damage is Repairable

  • Technology Attributes

  • Expanding the Capabilities of Radiotherapy

  • Technology Attributes

  • Increasing Life Expectancy with the Help of Monoclonal Antibodies

  • Gene Therapy for Retinitis Pigmentosa

  • Organoid Model for Preliminary Study

  • Technology Attributes

  • Big Pharma Exploring Exosome Therapeutics

  • Fiber-based Disks to Increase Cell Culture Yield

  • Simple Polymer Material Suitable for Various Cell Lines

  • Antibodies to Treat Metastatic Cancer

  • Ona Therapeutics Carries Out Pre-clinical Trials

  • Liver Cancer Detection by Viral Exposure Signature

  • Growth Opportunities

  • First-in-human Testing of Minimally Invasive Procedure for Treating Hydrocephalus

  • 2.5D Organoid Culture as Model for Bladder Cancer Studies

  • Growing Need for COVID-19 Portable Testing Kits

  • Opportunities Across Industries/ Applications

  • Gene-Edited Immune Cells Grow into Potent Tumor Killers

  • 3D Printing of Compliant Biomedical Sensors Directly on Organs

  • Prospective Neutralizing Antibodies Against COVID-19

  • Next-gen Sequencing Test for COVID-19

  • High-precision Cell Therapy for Blood Cancer

  • Industry Interactions

  • Key Contacts

For more information about this report visit https://www.researchandmarkets.com/r/4y4fyh

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005721/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Latest stories

  • These are the best discounted products from Nordstrom's beauty section

    If there's one thing we love, it's a good sale.

  • US STOCKS-S&P, Nasdaq close at record highs on optimism about Biden stimulus plan

    The S&P 500 and Nasdaq closed at record highs on Thursday, propelled by optimism about more pandemic relief under the Biden administration to support the economy after data showed a tepid labor market recovery. "We've had a very strong momentum going into this year and coming into the Biden administration... because of prospects of a bigger stimulus check and more spending in general," said Mohannad Aama, managing director at Beam Capital Management LLC in New York. The Dow Jones Industrial Average fell 12.37 points, or 0.04%, to 31,176.01, the S&P 500 gained 1.22 points, or 0.03%, to 3,853.07 and the Nasdaq Composite added 73.67 points, or 0.55%, to 13,530.92.

  • IBM Quarterly Revenue Miss Shows Cloud Struggles Continue

    (Bloomberg) -- International Business Machines Corp. reported quarterly revenue that missed analysts’ estimates, signaling Chief Executive Officer Arvind Krishna’s plans to shed legacy businesses and focus on cloud services will take more time to bear fruit.Sales fell 6.5% to $20.4 billion in the three months ended Dec. 31, the Armonk, New York-based company said Thursday in a statement. That was below the $20.75 billion analysts had forecast, on average, and marked the 10th consecutive quarter with no year-over-year increase in revenue. The shares fell in extended trading.Last October, Krishna announced he would spin off IBM’s managed infrastructure services unit into a separate publicly traded company. The division, which is currently part of IBM’s Global Technology Services division, handles day-to-day infrastructure service operations, like managing client data centers and traditional information-technology support for installing, repairing and operating equipment. While the unit accounts for about a quarter of IBM’s sales and staff, it has seen business shrink as customers embraced the shift to the cloud, and many clients delayed infrastructure upgrades during the pandemic. The spinoff is scheduled to be completed by end of 2021.Revenue declined across IBM’s business segments in the fourth quarter. Cloud and Cognitive Software, IBM’s biggest unit, saw revenue decrease 4.5% from a year earlier. That follows a 7% gain in that unit in the third quarter. Total cloud revenue increased 10% to $7.5 billion. In Global Technology Services, revenue fell 5.5% while sales from Global Business Services dropped 2.6%. Systems, which includes hardware and operating systems software, saw sales decline 18%.Krishna said the company’s actions to focus on cloud and artificial intelligence “will take hold,” and give him “confidence we can achieve revenue growth in 2021.” The company hasn’t given specific financial forecasts since it withdrew its annual projection for 2020 in April.IBM fell about 6% in extended trading after closing at $131.65 in New York. The stock has declined about 5% over the past 12 months.“It’s more or less a reflection of the difficult spot they’re in,” in trying to restructure the business, said Daniel Elman, an analyst at Nucleus Research.IBM seeks to distinguish itself from its bigger rivals in cloud, such as Amazon.com Inc. and Microsoft Corp., by offering a hybrid model, which assists clients in storing and computing data across on-premises infrastructure, private cloud services and servers run by public providers. Krishna was the driving force behind IBM’s $34 billion purchase of open source software provider Red Hat in 2018, the first step toward transitioning IBM into what it sees as a $1 trillion hybrid-cloud market, and which now leads much of the company’s growth. Red Hat revenue increased 19% in the fourth quarter to $1.3 billion.IBM continues to make acquisitions to bolster its cloud credentials. The company has made seven acquisitions focused on cloud and AI since October, Chief Financial Officer James Kavanaugh said in the statement, including Taos Mountain LLC, a firm that helps companies shift software and data online, and Instana, which manages cloud applications.Fourth-quarter earnings excluding some costs were $2.07 a share, beating the average analyst estimate of $1.79. Gross margin was 52.5%, 1.3 percentage points higher than analysts’ expected.(Updates with analyst comment in seventh paragraph. A previous version of this story corrected the spelling of the CEO’s name in first paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Apache Corporation Provides Fourth-Quarter Supplemental Information and Schedules Results Conference Call for Feb. 25, at 10 A.M. Central Time

    HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apache Corporation (Nasdaq: APA) today provided supplemental information regarding certain fourth-quarter 2020 financial and operational results. Supplemental quarterly informationTo further assist analysts with their fourth-quarter earnings models, the company is providing the following estimates: Estimated Average Realized Prices – 4Q20 Oil (bbl)NGL (bbl)Natural Gas (Mcf)United States$41.00$14.50$1.70International$44.50$33.50$3.20 Egypt tax barrels:10-11 MBoe/dRealized loss on commodity derivatives (before tax):$16 millionUnrealized gain on commodity derivatives (before tax):$14 millionDry hole costs (before tax):$57-60 million Fourth-quarter 2020 earnings callApache Corporation will host its fourth-quarter 2020 results conference call on Thursday, Feb. 25, at 10 a.m. Central time. The company will issue its earnings release after the market close on Wednesday, Feb. 24. The full text of the release will be available on the company's website at www.apachecorp.com. The conference call will be webcast from Apache's website at investor.apachecorp.com, and the webcast replay will be archived there as well. The conference call will also be available for playback by telephone for one week beginning at approximately 4 p.m. Central time, Feb. 25. To access the telephone playback, dial (855) 859-2056 or (404) 537-3406 for international calls. The conference access code is 7773126. About ApacheApache Corporation is an oil and gas exploration and production company with operations in the United States, Egypt and the United Kingdom and exploration activities offshore Suriname. Apache posts announcements, operational updates, investor information and press releases on its website, www.apachecorp.com. Specific information concerning Suriname, ESG performance and other investor-related topics are posted at investor.apachecorp.com. Forward-looking statementsThis news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by words such as “anticipates,” “intends,” “plans,” “seeks,” “believes,” “continues,” “could,” “estimates,” “expects,” “guidance,” “may,” “might,” “outlook,” “possibly,” “potential,” “projects,” “prospects,” “should,” “will,” “would,” and similar references to future periods, but the absence of these words does not mean that a statement is not forward-looking. These statements include, but are not limited to, statements about future plans, expectations and objectives for Apache’s operations, including statements about our capital plans, drilling plans, production expectations, asset sales, and monetizations. While forward-looking statements are based on assumptions and analyses made by us that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance, and financial condition to differ materially from our expectations. See “Risk Factors” in our 2019 Form 10-K and in our quarterly reports on Form 10-Q filed, and 2020 Form 10-K when filed, with the Securities and Exchange Commission for a discussion of risk factors that affect our business. Any forward-looking statement made by Apache in this news release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Apache undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future development or otherwise, except as may be required by law. ContactsInvestor: (281) 302-2286Gary ClarkMedia:(713) 296-7276 Phil WestWebsite: www.apachecorp.com APA-F

  • Magellan and Enterprise to Develop Joint Houston Crude Oil Futures Contract

    Magellan Midstream Partners, L.P. (NYSE: MMP) and Enterprise Products Partners L.P. (NYSE:EPD) today announced that affiliates of the two companies have entered into an agreement to jointly develop a futures contract for the physical delivery of crude oil in the Houston area in response to market interest for a Houston-based index with greater scale, flow assurance and price transparency. The quality specifications will be consistent with a West Texas Intermediate ("WTI") crude oil originating from the Permian Basin with delivery capabilities at either Magellan’s East Houston terminal or Enterprise’s ECHO terminal in Houston.

  • Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

  • Boston Private Reports Fourth Quarter and Full Year 2020 Results

    Boston Private Financial Holdings, Inc. (NASDAQ: BPFH) (the "Company" or "Boston Private") today reported fourth quarter 2020 Net income attributable to the Company of $25.0 million, compared to $22.7 million for the third quarter of 2020 and $21.2 million for the fourth quarter of 2019. Fourth quarter 2020 Diluted earnings per share were $0.30, compared to $0.28 in the third quarter of 2020 and $0.26 in the fourth quarter of 2019.

  • Intel Gives Upbeat Forecast on PC Demand; Shares Jump

    (Bloomberg) -- Intel Corp. gave an upbeat forecast for the current quarter on continued demand for personal computers that enable working and studying from home.The results, released before the market closed on Thursday, sent the shares higher in New York. The stock then dipped slightly in extended trading. Revenue in the period ending in March will be about $17.5 billion, the Santa Clara, California-based company said. This excludes the memory chip division Intel is selling. Analysts were looking for $16.2 billion on average, according to data compiled by Bloomberg.Intel sees strong demand for laptops through the first half of the year, Chief Financial Officer George Davis said in an interview. Earnings in the second part of the year will partly depend on whether corporations increase spending on new hardware, he added.“The question is will we see support from enterprise,” he said. “They’ve been very quiet.”The world’s largest chipmaker shared no new details about its manufacturing plans in its earnings statement on Thursday. The company will address this during a conference call with analysts later on Thursday. Investors have been waiting to see if Intel will outsource more production.Intel recently decided to replace Chief Executive Officer Bob Swan with Pat Gelsinger, a former insider who left in 2009 after decades at the company. It made the change after falling behind in manufacturing, a lapse that’s offering rivals the chance to make better chips for the first time in more than a decade.Read more: Intel Goes Back to Roots With Gelsinger to Regain Chip LeadSwan was due to announce a plan on Thursday to outsource more manufacturing to other companies or try to reclaim Intel’s leadership in production technology. Gelsinger takes over officially on Feb. 15 and he is taking more time to devise his own strategy.“Longer term, it goes beyond the make-vs.-buy decision,” Ambrish Srivastava, an analyst at BMO Capital Markets, said in a note published before Intel earnings. ‘’What we are looking for is how Intel addresses what appear to be recurring issues it has had on that front. For that, we will likely have to wait to hear from the new CEO.”Intel’s stock rose 6.5% to close at $62.46 in New York. The shares declined 17% in 2020 but have rebounded following Gelsinger’s appointment.While Intel is currently benefiting from strong PC demand, Gelsinger is taking the reins of a company in the midst of its worst crisis in at least a decade. It has been the largest chipmaker for most of the past 30 years dominating the $400 billion industry by making the best designs in its own cutting-edge factories. Most other U.S. chip companies shut or sold plants and tapped other firms to make the components. Intel held out, arguing that doing both improved each side of its operations and created better semiconductors.That strategy has crumbled in recent years as Intel struggled to introduce new production techniques on time. It is now lagging behind Taiwan Semiconductor Manufacturing Co. and Samsung Electronics Co., which make chips for Intel’s competitors. Intel has had talks with both Asian companies about producing some of its leading products, Bloomberg reported earlier this year.Intel’s personal computer chip division had revenue of $10.9 billion in the fourth quarter. Analysts expected $9.72 billion. Its higher-margin data center unit generated sales of $6.1 billion. Wall Street was looking for $5.37 billion.In Intel’s data center business, revenue from cloud service providers fell 15% from a year earlier. Enterprise and government sales slumped 25%. Volumes and average selling prices declined. Owners of large data centers are working their way through unused stockpiles of chips.In its PC business, Intel reported a 30% surge in laptop chip sales, even as average selling prices declined 15%.Fourth-quarter profit, excluding some items, was $1.52 a share on $20 billion of revenue, down 1% from a year earlier. Analysts had estimated $1.11 a share on revenue of $17.5 billion.Intel’s gross margin, the percentage of revenue remaining after deducting the cost of production, was 56.8%. This is a key indicator of the strength of its manufacturing and product pricing. Intel has historically delivered margins of about 60%.(Updates with CFO comments in fourth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

    ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine — dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1

  • These 3 Giants Could Keep the Stock Market Rally Going in 2021

    Stocks had a largely quiet day on Thursday, with major market benchmarks trading on either side of the unchanged mark as investors paused after a huge rally to begin the year. Momentum strategies have worked extraordinarily well over the past year, and investors still seem to be quite happy with what they're familiar with. Market leadership has come from the technology sector for a long time, and today, gains in Apple (NASDAQ: AAPL), NVIDIA (NASDAQ: NVDA), and Intel (NASDAQ: INTC) played the biggest role in pushing the Nasdaq higher and keeping stocks at or near record levels.

  • Biden Voters Are More Likely Than Trump Voters To Favor Bipartisan Efforts

    Half of the voters who supported President Joe Biden in last year's electionthink he should try to compromise with Republicans in Washington, a newHuffPost/YouGov survey finds.

  • It's OK To Have Questions About COVID-19 Vaccines. Here Are Doctors' Answers

    TORONTO -- It's totally normal to have questions about any aspect of yourhealth care.

  • CrossAmerica Partners LP Maintains Quarterly Distribution

    Allentown, Jan. 21, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution ·Quarterly distribution of $0.5250 per unit attributable to the fourth quarter of 2020 ALLENTOWN, PA (January 21, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the fourth quarter of 2020 (annualized $2.10 per unit). The distribution attributable to the fourth quarter is payable on February 9, 2021 to all unitholders of record on February 2, 2021. CrossAmerica will host a conference call on March 2nd at 9:00 a.m. Eastern Time to discuss year-end/fourth quarter earnings results, which will be released after the market closes on Monday, March 1. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator, and owner and lessor of real estate used in the retail distribution of motor fuels. Its general partner, CrossAmerica GP LLC, is indirectly owned and controlled by entities affiliated with Joseph V. Topper, Jr., the founder of CrossAmerica Partners and a member of the board of the general partner since 2012. Formed in 2012, CrossAmerica Partners LP is a distributor of branded and unbranded petroleum for motor vehicles in the United States and distributes fuel to approximately 1,700 locations and owns or leases approximately 1,100 sites. With a geographic footprint covering 34 states, the Partnership has well-established relationships with several major oil brands, including ExxonMobil, BP, Shell, Chevron, Sunoco, Valero, Gulf, Citgo, Marathon and Phillips 66. CrossAmerica Partners ranks as one of ExxonMobil's largest distributors by fuel volume in the United States and in the top 10 for additional brands. For additional information, please visit www.crossamericapartners.com. Forward Looking Statement Statements contained in this release that state the Partnership’s or management's expectations or predictions of the future are forward-looking statements. The words "believe," "expect," "should," "intends," "estimates," "target," "plan" and other similar expressions identify forward-looking statements. It is important to note that actual results could differ materially from those projected in such forward-looking statements. For more information concerning factors that could cause actual results to differ from those expressed or forecasted, see CrossAmerica's Forms 10-Q or Form 10-K filed with the Securities and Exchange Commission and available on CrossAmerica's website at www.crossamericapartners.com. The Partnership undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise. Note to Non-United States Investors: This release is intended to be a qualified notice under Treasury Regulation Section 1.1446-4(b). Brokers and nominees should treat one hundred percent (100%) of CrossAmerica Partners LP’s distributions to non-U.S. investors as attributable to income that is effectively connected with a United States trade or business. Accordingly, CrossAmerica Partners LP’s distributions to non-U.S. investors are subject to federal income tax withholding at the highest applicable effective tax rate. Contact – Randy Palmer, rpalmer@caplp.com or 210-742-8316

  • Afya Limited Announces Closing of the Acquisition of iClinic

    NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA) in addition to the Press Release released by the Company on October 13, 2020, today announced the closing of its acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of iClinic. iClinic is a SaaS model physician focused technology company and the leading medical practice management software in Brazil. They empower doctors to be more independent and have more control over their careers by digitalizing their daily routine, so they can increase their productivity and deliver better healthcare services. Their portfolio includes: Electronic Medical Record: first electronic medical record as a SaaS model in Brazil focused on the physician experience; Clinical Management System: with this software doctors can schedule patients online, organize their financial records, use marketing tools to promote their clinics and others;Telemedicine: platform to provide online consultations fully integrated with doctor’s schedule and records; andPhysicians Marketplace: website that connects doctors and patients to schedule consultations. iClinic as of today has more than 25,000 monthly active users of which 12,400 are monthly active subscribers. The platform performs more than 790,000 medical consultations per month, which around 7,800 are through telemedicine and prescribes more than 420,000 electronic medical prescriptions and 400,000 image exams and lab tests per month. The database created in the platform through this performance has more than 16 million registered patients. The net purchase price (equity value) paid to sellers was R$191.1 million, of which: (i) 62.6% was paid in cash, and (ii) 37.4% in Afya’s class A common shares. About Afya Afya is a leading medical education group in Brazil based on number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering digital products to help doctors enhance their healthcare services through their whole career. Contact: Investor Relations: ir@afya.com.br

  • "People with disabilities must be exempted from pool closures now": CUPE Ontario

    Provincial restrictions must immediately allow exemptions for people with disabilities wishing to use indoor municipal facilities for physical therapy or rehabilitation, says the Canadian Union of Public Employees (CUPE) Ontario.

  • KBRA Releases Research – CRE Securitization: LIBOR to SOFR Path Paved but Curves Lie Ahead

    Kroll Bond Rating Agency (KBRA) releases research on the commercial real estate (CRE) securitization industry ahead of the switchover to the Secured Overnight Finance Rate (SOFR) benchmark from LIBOR.

  • Knoll, Inc. to Announce 2020 Fourth Quarter and Full Year Results on February 10, 2021

    Company to Host Q&A Conference Call at 5:30 p.m. ETEAST GREENVILLE, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Knoll, Inc. (NYSE:KNL), a leading designer and manufacturer of furnishings and coverings for the workplace and home, today announced that it plans to report financial results for the fourth quarter and full year 2020 on Wednesday, February 10, 2021, following the close of the market. In addition, Knoll, Inc. will host a Q&A conference call at 5:30 p.m. ET on Wednesday, February 10, 2021 to respond to questions. To access the live Q&A call: North America (844) 778-4138International (661) 378-9550Q&A Conference ID 1895549 A replay of the Q&A conference call will be available through February 17, 2021 by dialing (855) 859-2056 or (404) 537-3406 and entering passcode 1895549. About Knoll Knoll, Inc. is a constellation of design-driven brands and people, working together with our clients in person and digitally to create inspired modern interiors. Our internationally recognized portfolio includes furniture, textiles, leathers, accessories, and architectural and acoustical elements. Our brands — Knoll Office, KnollStudio, KnollTextiles, KnollExtra, Spinneybeck | FilzFelt, Edelman Leather, HOLLY HUNT, DatesWeiser, Muuto, and Fully — reflect our commitment to modern design that meets the diverse requirements of high performance workplaces, work from home settings and luxury residential interiors. A recipient of the National Design Award for Corporate and Institutional Achievement from the Smithsonian`s Cooper-Hewitt, National Design Museum, Knoll, Inc. is aligned with the U.S. Green Building Council and the Canadian Green Building Council and can help organizations achieve the Leadership in Energy and Environmental Design (LEED) workplace certification. Our products can also help clients comply with the International Living Future Institute to achieve Living Building Challenge Certification, and with the International WELL Building Institute to attain WELL Building Certification. Knoll, Inc. is the founding sponsor of the World Monuments Fund Modernism at Risk program. Investors: Charles Rayfield Senior Vice President and Chief Financial OfficerTel 215 679-1703crayfield@knoll.com Media: David E. BrightSenior Vice President, CommunicationsTel 212 343-4135dbright@knoll.com

  • Why Investors Dumped Riot Blockchain Stock Today

    Shares of bitcoin-mining company Riot Blockchain (NASDAQ: RIOT) continued their decline on Thursday because the price of bitcoin keeps falling. As of 3 p.m. EST, Riot Blockchain stock was down 10%. Riot Blockchain mines bitcoin to generate revenue.

  • Photo comes back to bite Scott Morrison amid Australia Day debate

    The cricket world has called out Scott Morrison over his comments about cricket's change to Australia Day.

  • Canada GG quits after harassment report

    Canada's governor-general has quit amid allegations of workplace harassment, resigning just hours after a report on the issue was handed to senior officials.